Special correlation between diet and MASLD: positive or negative? | Cell & Bioscience
Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691–702.
Google Scholar
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–86.
Google Scholar
Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab. 2021;50:101238.
Google Scholar
Scoditti E, Sabatini S, Carli F, Gastaldelli A. Hepatic glucose metabolism in the steatotic liver. Nat Rev Gastroenterol Hepatol. 2024;21(5):319–34.
Google Scholar
Li Y, Yang P, Ye J, Xu Q, Wu J, Wang Y. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 2024;23(1):117.
Google Scholar
Hsu YJ, Wang CY, Lee MC, Huang CC. Hepatoprotection by traditional essence of ginseng against carbon tetrachloride-induced liver damage. Nutrients. 2020;12(10):3214.
Google Scholar
Gallage S, Avila JEB, Ramadori P, Focaccia E, Rahbari M, Ali A, et al. A researcher’s guide to preclinical mouse NASH models. Nat Metab. 2022;4(12):1632–49.
Google Scholar
Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). 2018;38(1):27.
Google Scholar
Du Z, Lin L, Li Y, Sun M, Liang Q, Sun Z, et al. Combined exposure to PM(2.5) and high-fat diet facilitates the hepatic lipid metabolism disorders via ROS/miR-155/PPARgamma pathway. Free Radic Biol Med. 2022;190:16–27.
Google Scholar
Zhu W, Hong Y, Tong Z, He X, Li Y, Wang H, et al. Activation of hepatic adenosine A1 receptor ameliorates MASH via inhibiting SREBPs maturation. Cell Rep Med. 2024;5(3):101477.
Google Scholar
Luo W, Dai J, Liu J, Huang Y, Zheng Z, Xu P, et al. PACAP attenuates hepatic lipid accumulation through the FAIM/AMPK/IRβ axis during overnutrition. Mol Metab. 2022;65:101584.
Google Scholar
Xia Q, Lu F, Chen Y, Li J, Huang Z, Fang K, et al. 6-Gingerol regulates triglyceride and cholesterol biosynthesis to improve hepatic steatosis in MAFLD by activating the AMPK-SREBPs signaling pathway. Biomed Pharmacother. 2024;170:116060.
Google Scholar
Sommerauer C, Gallardo-Dodd CJ, Savva C, Hases L, Birgersson M, Indukuri R, et al. Estrogen receptor activation remodels TEAD1 gene expression to alleviate hepatic steatosis. Mol Syst Biol. 2024;20(4):374–402.
Google Scholar
Huang SJ, Chen SQ, Lin Y, Yang HY, Ran J, Yan FF, et al. Maternal nicotine exposure aggravates metabolic associated fatty liver disease via PI3K/Akt signaling in adult offspring mice. Liver Int. 2021;41(8):1867–78.
Google Scholar
Cheng X, Baki VB, Moran M, Liu B, Yu J, Zhao M, et al. Liver matrin-3 protects mice against hepatic steatosis and stress response via constitutive androstane receptor. Mol Metab. 2024;86:101977.
Google Scholar
Jiang Y, Luo P, Cao Y, Peng D, Huo S, Guo J, et al. The role of STAT3/VAV3 in glucolipid metabolism during the development of HFD-induced MAFLD. Int J Biol Sci. 2024;20(6):2027–43.
Google Scholar
Jiang P, Zeng Y, Yang W, Li L, Zhou L, Xiao L, et al. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies. Biomed Pharmacother. 2024;174:116485.
Google Scholar
Yang JW, Zou Y, Chen J, Cui C, Song J, Yang MM, et al. Didymin alleviates metabolic dysfunction-associated fatty liver disease (MAFLD) via the stimulation of Sirt1-mediated lipophagy and mitochondrial biogenesis. J Transl Med. 2023;21(1):921.
Google Scholar
Mu JK, Zi L, Li YQ, Yu LP, Cui ZG, Shi TT, et al. Jiuzhuan Huangjing Pills relieve mitochondrial dysfunction and attenuate high-fat diet-induced metabolic dysfunction-associated fatty liver disease. Biomed Pharmacother. 2021;142:112092.
Google Scholar
Qiu YY, Zhang J, Zeng FY, Zhu YZ. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Pharmacol Res. 2023;192:106786.
Google Scholar
Choi SW, Oh H, Park SY, Cho W, Abd El-Aty AM, Baygutalp NK, et al. Netrin-1 attenuates hepatic steatosis via UNC5b/PPARgamma-mediated suppression of inflammation and ER stress. Life Sci. 2022;311(Pt B):121149.
Google Scholar
Sun F, Yang Y, Jia L, Dong QQ, Hu W, Tao H, et al. TET3 boosts hepatocyte autophagy and impairs non-alcoholic fatty liver disease by increasing ENPP1 promoter hypomethylation. Free Radic Biol Med. 2024;218:166–77.
Google Scholar
Yuan Z, Qiao H, Wang Z, Wang H, Han M, Zhang W, et al. Taohe Chengqi decoction alleviated metabolic-associated fatty liver disease by boosting branched chain amino acids catabolism in the skeletal muscles of type 2 diabetes mellitus. Phytomedicine. 2024;126:155315.
Google Scholar
Sahin C, Melanson JR, Le Billan F, Magomedova L, Ferreira TAM, Oliveira AS, et al. A novel fatty acid mimetic with pan-PPAR partial agonist activity inhibits diet-induced obesity and metabolic dysfunction-associated steatotic liver disease. Mol Metab. 2024;85:101958.
Google Scholar
Lee WH, Kim SG. AMPK-dependent metabolic regulation by PPAR agonists. PPAR Res. 2010;2010:1–10.
Google Scholar
Ma C, Wang Z, Xia R, Wei L, Zhang C, Zhang J, et al. Danthron ameliorates obesity and MAFLD through activating the interplay between PPARalpha/RXRalpha heterodimer and adiponectin receptor 2. Biomed Pharmacother. 2021;137:111344.
Google Scholar
Gebreyesus LH, Choi S, Neequaye P, Mahmoud M, Mahmoud M, Ofosu-Boateng M, et al. Pregnane X receptor knockout mitigates weight gain and hepatic metabolic dysregulation in female C57BL/6 J mice on a long-term high-fat diet. Biomed Pharmacother. 2024;173:116341.
Google Scholar
Morgan D, Garg M, Tergaonkar V, Tan SY, Sethi G. Pharmacological significance of the non-canonical NF-kappaB pathway in tumorigenesis. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188449.
Google Scholar
Lyu Y, Yang X, Yang L, Dai J, Qin H, Zhou Y, et al. Lipid nanoparticle-mediated hepatocyte delivery of siRNA and silibinin in metabolic dysfunction-associated steatotic liver disease. J Control Release. 2024;373:385–98.
Google Scholar
Zakaria Z, Othman ZA, Suleiman JB, Che Jalil NA, Ghazali WSW, Nna VU, et al. Hepatoprotective effect of bee bread in metabolic dysfunction-associated fatty liver disease (MAFLD) rats: impact on oxidative stress and inflammation. Antioxidants (Basel). 2021;10(12):2031.
Google Scholar
Wei Y, Jiang Y, Zhu J, Zhang Z, Li M, Zheng S, et al. CD36-mediated uptake of oxidized LDL induces double-negative regulatory T cell ferroptosis in metabolic dysfunction-associated steatotic liver disease. Metabolism. 2025;164:156127.
Google Scholar
Wang YF, Zhang WL, Li ZX, Liu Y, Tan J, Yin HZ, et al. METTL14 downregulation drives S100A4(+) monocyte-derived macrophages via MyD88/NF-kappaB pathway to promote MAFLD progression. Signal Transduct Target Ther. 2024;9(1):91.
Google Scholar
Kim K, Kim MH, Kang JI, Baek JI, Jeon BM, Kim HM, et al. Ginsenoside F2 restrains hepatic steatosis and inflammation by altering the binding affinity of liver X receptor coregulators. J Ginseng Res. 2024;48(1):89–97.
Google Scholar
Cheng L, Chen T, Guo M, Liu P, Qiao X, Wei Y, et al. Glycoursodeoxycholic acid ameliorates diet-induced metabolic disorders with inhibiting endoplasmic reticulum stress. Clin Sci (Lond). 2021;135(14):1689–706.
Google Scholar
Qin D, Pan P, Lyu B, Chen W, Gao Y. Lupeol improves bile acid metabolism and metabolic dysfunction-associated steatotic liver disease in mice via FXR signaling pathway and gut-liver axis. Biomed Pharmacother. 2024;177:116942.
Google Scholar
Chen Y, Xie C, Lei Y, Ye D, Wang L, Xiong F, et al. Theabrownin from Qingzhuan tea prevents high-fat diet-induced MASLD via regulating intestinal microbiota. Biomed Pharmacother. 2024;174:116582.
Google Scholar
Collins SL, Stine JG, Bisanz JE, Okafor CD, Patterson AD. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol. 2023;21(4):236–47.
Google Scholar
Chen J, Xiao Y, Li D, Zhang S, Wu Y, Zhang Q, et al. New insights into the mechanisms of high-fat diet mediated gut microbiota in chronic diseases. Imeta. 2023;2(1):e69.
Google Scholar
Zhang M, Barroso E, Ruart M, Pena L, Peyman M, Aguilar-Recarte D, et al. Elafibranor upregulates the EMT-inducer S100A4 via PPARbeta/delta. Biomed Pharmacother. 2023;167:115623.
Google Scholar
Pagire HS, Pagire SH, Jeong BK, Choi WI, Oh CJ, Lim CW, et al. Discovery of a peripheral 5HT(2A) antagonist as a clinical candidate for metabolic dysfunction-associated steatohepatitis. Nat Commun. 2024;15(1):645.
Google Scholar
Meng F, Khoso MH, Kang K, He Q, Cao Y, Jiang X, et al. FGF21 ameliorates hepatic fibrosis by multiple mechanisms. Mol Biol Rep. 2021;48(11):7153–63.
Google Scholar
Gallego-Durán R, Ampuero J, Maya-Miles D, Pastor-Ramírez H, Montero-Vallejo R, Rivera-Esteban J, et al. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression. United Eur Gastroenterol J. 2024;12:1056–68.
Google Scholar
Yu W, Zhang Y, Sun L, Huang W, Li X, Xia N, et al. Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution. Metabolism. 2024;155:155911.
Google Scholar
Foglia B, Sutti S, Cannito S, Rosso C, Maggiora M, Casalino A, et al. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis. Front Immunol. 2024;15:1342404.
Google Scholar
Lan T, Geng XJ, Zhang SJ, Zeng XX, Ying JJ, Xu Y, et al. Si-Ni-San inhibits hepatic Fasn expression and lipid accumulation in MAFLD mice through AMPK/p300/SREBP-1c axis. Phytomedicine. 2024;123:155209.
Google Scholar
Kjaergaard K, Daugaard Mikkelsen AC, Landau AM, Eriksen PL, Hamilton-Dutoit S, Magnusson NE, et al. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation. JHEP Rep. 2024;6(3):100992.
Google Scholar
Cui Y, Guo C, Xia Z, Xue Y, Song B, Hu W, et al. Exploring the therapeutic potential of a nano micelle containing a carbon monoxide-releasing molecule for metabolic-associated fatty liver disease by modulating hypoxia-inducible factor-1alpha. Acta Biomater. 2023;169:500–16.
Google Scholar
Santos-Sánchez G, Cruz-Chamorro I, Álvarez-Ríos AI, Fernández-Santos JM, Vázquez-Román MV, Rodríguez-Ortiz B, et al. Lupinus angustifolius protein hydrolysates reduce abdominal adiposity and ameliorate metabolic associated fatty liver disease (MAFLD) in western diet fed-ApoE(-/-) mice. Antioxidants (Basel). 2021;10(8):1222.
Google Scholar
Deng Y, Zhao Z, Sheldon M, Zhao Y, Teng H, Martinez C, et al. LIFR regulates cholesterol-driven bidirectional hepatocyte-neutrophil cross-talk to promote liver regeneration. Nat Metab. 2024;6(9):1756–74.
Google Scholar
Burbano de Lara S, Kemmer S, Biermayer I, Feiler S, Vlasov A, D’Alessandro LA, et al. Basal MET phosphorylation is an indicator of hepatocyte dysregulation in liver disease. Mol Syst Biol. 2024;20(3):187–216.
Google Scholar
Yan S, Zhang S, Du A, Miao H, Lu B, Huang Z, et al. Network pharmacology-based identification of significant pathway for protection of Yinhuang granule in a mice model of metabolic-associated fatty liver disease. Phytomedicine. 2021;91:153666.
Google Scholar
Sun X, Li X, Jia H, Wang H, Shui G, Qin Y, et al. Nuclear factor E2-related factor 2 mediates oxidative stress-induced lipid accumulation in adipocytes by increasing adipogenesis and decreasing lipolysis. Antioxid Redox Signal. 2020;32(3):173–92.
Google Scholar
Zeng H, Tang C, Lin B, Yu M, Wang X, Wang J, et al. The regulation effect of GLUT9/SLC2A9 on intrahepatic uric acid level and metabolic associated fatty liver disease. Hep Intl. 2022;16(5):1064–74.
Google Scholar
Luo J, Lu Z, Zhong Z, Pi M, Xiong Y, Li L, et al. ALDH2 deficiency exacerbates MCD-diet induced MASLD by modulating bile acid metabolism. Free Radical Biol Med. 2024;212:34–48.
Google Scholar
Tong J, Li D, Meng H, Sun D, Lan X, Ni M, et al. Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease. Acta Pharm Sin B. 2022;12(9):3650–66.
Google Scholar
Policarpo S, Carvalhana S, Craciun A, Crespo RR, Cortez-Pinto H. Do MAFLD patients with harmful alcohol consumption have a different dietary intake? Nutrients. 2022;14(7):1335.
Google Scholar
Schenker RB, Machle CJ, Schmidt KA, Allayee H, Kohli R, Goran MI. Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity. Liver Int. 2024;44(8):1768–74.
Google Scholar
Rispo A, Imperatore N, Guarino M, Tortora R, Alisi A, Cossiga V, et al. Metabolic-associated fatty liver disease (MAFLD) in coeliac disease. Liver Int. 2021;41(4):788–98.
Google Scholar
Cohen CC, Li KW, Alazraki AL, Beysen C, Carrier CA, Cleeton RL, et al. Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease. J Clin Invest. 2021;131(24):e150996. https://doi.org/10.1172/JCI150996
Long F, Bhatti MR, Kellenberger A, Sun W, Modica S, Horing M, et al. A low-carbohydrate diet induces hepatic insulin resistance and metabolic associated fatty liver disease in mice. Mol Metab. 2023;69:101675.
Google Scholar
De Nucci S, Bonfiglio C, Donvito R, Di Chito M, Cerabino N, Rinaldi R, et al. Effects of an eight week very low-calorie ketogenic diet (VLCKD) on white blood cell and platelet counts in relation to metabolic dysfunction-associated steatotic liver disease (MASLD) in subjects with overweight and obesity. Nutrients. 2023;15(20):4468.
Google Scholar
Sila A, De Nucci S, Bonfiglio C, Di Stasi V, Cerabino N, Di Chito M, et al. Higher-level steatosis is associated with a greater decrease in metabolic dysfunction-associated steatoic liver disease after eight weeks of a very low-calorie ketogenic diet (VLCKD) in subjects affected by overweight and obesity. Nutrients. 2024;16(6):874.
Google Scholar
Rinaldi R, De Nucci S, Donghia R, Donvito R, Cerabino N, Di Chito M, et al. Gender differences in liver steatosis and fibrosis in overweight and obese patients with metabolic dysfunction-associated steatotic liver disease before and after 8 weeks of very low-calorie ketogenic diet. Nutrients. 2024;16(10):1408.
Google Scholar
Zhang X, Daniel CR, Soltero V, Vargas X, Jain S, Kanwal F, et al. A study of dietary patterns derived by cluster analysis and their association with metabolic dysfunction-associated steatotic liver disease severity among hispanic patients. Am J Gastroenterol. 2024;119(3):505–11.
Google Scholar
Mogna-Pelaez P, Riezu-Boj JI, Milagro FI, Herrero JI, Elorz M, Benito-Boillos A, et al. Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: results from the Fatty Liver in Obesity trial. Clin Nutr. 2024;43(7):1770–81.
Google Scholar
Del Bo C, Perna S, Allehdan S, Rafique A, Saad S, AlGhareeb F, et al. Does the Mediterranean diet have any effect on lipid profile, central obesity and liver enzymes in non-alcoholic fatty liver disease (NAFLD) subjects? A systematic review and meta-analysis of randomized control trials. Nutrients. 2023;15(10):2250.
Google Scholar
Quetglas-Llabres MM, Monserrat-Mesquida M, Bouzas C, Llompart I, Mateos D, Casares M, et al. Mediterranean diet improves plasma biomarkers related to oxidative stress and inflammatory process in patients with non-alcoholic fatty liver disease. Antioxidants (Basel). 2023;12(4):833.
Google Scholar
Kwon YJ, Choi JE, Hong KW, Lee JW. Interplay of Mediterranean-diet adherence, genetic factors, and metabolic dysfunction-associated steatotic liver disease risk in Korea. J Transl Med. 2024;22(1):591.
Google Scholar
Heredia NI, Thrift AP, Ramsey DJ, Loomba R, El-Serag HB. Association of diet quality with metabolic (dysfunction) associated fatty liver disease in veterans in primary care. Nutrients. 2023;15(11):2598.
Google Scholar
Huang X, Gan D, Fan Y, Fu Q, He C, Liu W, et al. The associations between healthy eating patterns and risk of metabolic dysfunction-associated steatotic liver disease: a case-control study. Nutrients. 2024;16(12):1956.
Google Scholar
Jain AK, Buchannan P, Yates KP, Belt P, Schwimmer JB, Rosenthal P, et al. Nutrition assessment and MASH severity in children using the Healthy Eating Index. Hepatol Commun. 2023;7(12):e0320. https://doi.org/10.1097/HC9.0000000000000320
Lewis MY, Yonemori K, Ross A, Wilkens LR, Shepherd J, Cassel K, et al. Effect of intermittent vs. continuous energy restriction on visceral fat: protocol for the healthy diet and lifestyle study 2 (HDLS2). Nutrients. 2024;16(10):1478.
Google Scholar
Gallage S, Ali A, Barragan Avila JE, Seymen N, Ramadori P, Joerke V, et al. A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARalpha and PCK1. Cell Metab. 2024;36(6):1371–93.
Google Scholar
Xia J, Guo W, Hu M, Jin X, Zhang S, Liu B, et al. Resynchronized rhythmic oscillations of gut microbiota drive time-restricted feeding induced nonalcoholic steatohepatitis alleviation. Gut Microbes. 2023;15(1):2221450.
Google Scholar
Rozanski G, Pheby D, Newton JL, Murovska M, Zalewski P, Slomko J. Effect of different types of intermittent fasting on biochemical and anthropometric parameters among patients with metabolic-associated fatty liver disease (MAFLD)—a systematic review. Nutrients. 2021;14(1):91.
Google Scholar
Lee JH, Park J, Ahn SB. Different associations of coffee consumption with the risk of incident metabolic dysfunction-associated steatotic liver disease and advanced liver fibrosis. Nutrients. 2023;16(1):140.
Google Scholar
Arroyave-Ospina JC, Buist-Homan M, Schmidt M, Moshage H. Protective effects of caffeine against palmitate-induced lipid toxicity in primary rat hepatocytes is associated with modulation of adenosine receptor A1 signaling. Biomed Pharmacother. 2023;165:114884.
Google Scholar
Refaat B, Abdelghany AH, Ahmad J, Abdalla OM, Elshopakey GE, Idris S, et al. Vitamin D(3) enhances the effects of omega-3 oils against metabolic dysfunction-associated fatty liver disease in rat. BioFactors. 2022;48(2):498–513.
Google Scholar
Chen Q, Zhao L, Mei L, Zhao X, Han P, Liu J, et al. Vitamin C and vitamin D(3) alleviate metabolic-associated fatty liver disease by regulating the gut microbiota and bile acid metabolism via the gut-liver axis. Front Pharmacol. 2023;14:1163694.
Google Scholar
Lee HS, Kim Y. Aucklandia lappa causes cell wall damage in Candida albicans by reducing chitin and (1,3)-beta-D-glucan. J Microbiol Biotechnol. 2020;30(7):967–73.
Google Scholar
Ebrahimpour-Koujan S, Sohrabpour AA, Giovannucci E, Vatannejad A, Esmaillzadeh A. Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial. Nutr J. 2024;23(1):24.
Google Scholar
Orliacq J, Perez-Cornago A, Parry SA, Kelly RK, Koutoukidis DA, Carter JL. Associations between types and sources of dietary carbohydrates and liver fat: a UK Biobank study. BMC Med. 2023;21(1):444.
Google Scholar
Armandi A, Bespaljko H, Mang A, Huber Y, Michel M, Labenz C, et al. Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: a randomised, controlled proof-of-concept study. Aliment Pharmacol Ther. 2024;59(10):1212–22.
Google Scholar
Kazmierczak-Siedlecka K, Maciejewska-Markiewicz D, Sykulski M, Gruszczynska A, Herman-Izycka J, Wylezol M, et al. Gut microbiome-how does two-month consumption of fiber-enriched rolls change microbiome in patients suffering from MASLD? Nutrients. 2024;16(8):1173.
Google Scholar
Jaeger JW, Brandt A, Gui W, Yergaliyev T, Hernandez-Arriaga A, Muthu MM, et al. Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression. JHEP Rep. 2024;6(3):100987.
Google Scholar
Rosas-Campos R, Sandoval-Rodríguez AS, Rodríguez-Sanabria JS, Vazquéz-Esqueda ÁO, Alfaro-Martinez CR, Escutia-Gutiérrez R, et al. A novel foodstuff mixture improves the gut-liver axis in MASLD mice and the gut microbiota in overweight/obese patients. Antioxidants (Basel). 2024;13(6):664.
Google Scholar
Rao Y, Kuang Z, Li C, Guo S, Xu Y, Zhao D, et al. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut Microbes. 2021;13(1):1–19.
Google Scholar
Jin S, Chen P, Yang J, Li D, Liu X, Zhang Y, et al. Phocaeicola vulgatus alleviates diet-induced metabolic dysfunction-associated steatotic liver disease progression by downregulating histone acetylation level via 3-HPAA. Gut Microbes. 2024;16(1):2309683.
Google Scholar
Larsen IS, Choi BS, Foh B, Kristensen NN, Ouellette A, Haller RF, et al. Experimental diets dictate the metabolic benefits of probiotics in obesity. Gut Microbes. 2023;15(1):2192547.
Google Scholar
Zhao S, Jang C, Liu J, Uehara K, Gilbert M, Izzo L, et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature. 2020;579(7800):586–91.
Google Scholar
Hrncir T, Trckova E, Hrncirova L. Synergistic effects of fructose and food preservatives on metabolic dysfunction-associated steatotic liver disease (MASLD): from gut microbiome alterations to hepatic gene expression. Nutrients. 2024;16(21):3722.
Google Scholar
Choi KJ, Yoon MY, Kim JE, Yoon SS. Gut commensal Kineothrix alysoides mitigates liver dysfunction by restoring lipid metabolism and gut microbial balance. Sci Rep. 2023;13(1):14668.
Google Scholar
Zhang F, Lo EKK, Chen J, Wang K, Felicianna, Ismaiah MJ, et al. Probiotic mixture ameliorates a diet-induced MASLD/MASH murine model through the regulation of hepatic lipid metabolism and the gut microbiome. J Agric Food Chem. 2024;72(15):8536–49.
Vacca M, Kamzolas I, Harder LM, Oakley F, Trautwein C, Hatting M, et al. An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD). Nat Metab. 2024;6(6):1178–96.
Google Scholar
Heller B, Reiter FP, Leicht HB, Fiessler C, Bergheim I, Heuschmann PU, et al. Salt-intake-related behavior varies between sexes and is strongly associated with daily salt consumption in obese patients at high risk for MASLD. Nutrients. 2023;15(18):3942.
Google Scholar
Charlot A, Bringolf A, Mallard J, Charles AL, Niederhoffer N, Duteil D, et al. Hypercaloric low-carbohydrate high-fat diet protects against the development of nonalcoholic fatty liver disease in obese mice in contrast to isocaloric Western diet. Front Nutr. 2024;11:1366883.
Google Scholar
Hu C, Huang R, Li R, Ning N, He Y, Zhang J, et al. Low-carbohydrate and low-fat diet with metabolic-dysfunction-associated fatty liver disease. Nutrients. 2023;15(22):4763.
Google Scholar
Hata S, Okamura T, Kobayashi A, Bamba R, Miyoshi T, Nakajima H, et al. Gut microbiota changes by an SGLT2 inhibitor, luseogliflozin, alters metabolites compared with those in a low carbohydrate diet in db/db mice. Nutrients. 2022;14(17):3531.
Google Scholar
Rohwer N, Jelleschitz J, Hohn A, Weber D, Kuhl AA, Wang C, et al. Prevention of colitis-induced liver oxidative stress and inflammation in a transgenic mouse model with increased omega-3 polyunsaturated fatty acids. Redox Biol. 2023;64:102803.
Google Scholar
Luo W, Xu Q, Wang Q, Wu H, Hua J. Effect of modulation of PPAR-gamma activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. Sci Rep. 2017;7:44612.
Google Scholar
Espirito Santo SG, Monte MG, Polegato BF, Barbisan LF, Romualdo GR. Protective effects of omega-3 supplementation against doxorubicin-induced deleterious effects on the liver and kidneys of rats. Molecules. 2023;28(7):3004.
Google Scholar
Hn L, Yj S. Resolvin D1-mediated NOX2 inactivation rescues macrophages undertaking efferocytosis from oxidative stress-induced apoptosis. Biochem Pharmacol. 2013;86(6):759–69.
Google Scholar
Pipitone RM, Lupo G, Zito R, Javed A, Petta S, Pennisi G, et al. The PD-1/PD-L1 Axis in the Biology of MASLD. Int J Mol Sci. 2024;25(7):3671.
Google Scholar
Ay U, Lenicek M, Haider RS, Classen A, van Eijk H, Koelfat KVK, et al. Microbially conjugated bile salts found in human bile activate the bile salt receptors TGR5 and FXR. Hepatol Commun. 2024;8(4):e0383. https://doi.org/10.1097/HC9.0000000000000383
Li M, Wang S, Li Y, Zhao M, Kuang J, Liang D, et al. Gut microbiota-bile acid crosstalk contributes to the rebound weight gain after calorie restriction in mice. Nat Commun. 2022;13(1):2060.
Google Scholar
link
